<info type="ChemicalEntity">dehydroepiandrosterone</info> in <info type="ChemicalEntity">amphetamine</info>-induced <info type="DiseaseOrPhenotypicFeature">schizophrenia</info> models in <info type="OrganismTaxon">mice</info>.

<info type="GeneOrGeneProduct">OBJECTIVE</info>: To examine the effects of <info type="ChemicalEntity">dehydroepiandrosterone</info> (<info type="ChemicalEntity">DHEA</info>) on animal models of <info type="DiseaseOrPhenotypicFeature">schizophrenia</info>. <info type="GeneOrGeneProduct">METHODS</info>: Seventy <info type="CellLine">Swiss albino female mice</info> (25-35 g) were divided into 4 groups: <info type="ChemicalEntity">amphetamine</info>-free (control), <info type="ChemicalEntity">amphetamine</info>, 50, and 100 mg/kg <info type="ChemicalEntity">DHEA</info>. The <info type="ChemicalEntity">DHEA</info> was administered intraperitoneally (ip) for 5 days. <info type="ChemicalEntity">Amphetamine</info> (3 mg/kg ip) induced <info type="DiseaseOrPhenotypicFeature">hyper locomotion</info>, <info type="ChemicalEntity">apomorphine</info> (1.5 mg/kg subcutaneously [sc]) induced <info type="DiseaseOrPhenotypicFeature">climbing</info>, and <info type="ChemicalEntity">haloperidol</info> (1.5 mg/kg sc) induced <info type="DiseaseOrPhenotypicFeature">catalepsy</info> tests were used as animal models of <info type="DiseaseOrPhenotypicFeature">schizophrenia</info>. The study was conducted at the Animal Experiment Laboratories, Department of Pharmacology, Medical School, <info type="OrganismTaxon">Eskisehir Osmangazi University</info>, <info type="OrganismTaxon">Eskisehir</info>, <info type="OrganismTaxon">Turkey</info> between March and May 2012. Statistical analysis was carried out using <info type="GeneOrGeneProduct">Kruskal-Wallis test</info> for <info type="DiseaseOrPhenotypicFeature">hyper locomotion</info>, and one-way <info type="GeneOrGeneProduct">ANOVA</info> for climbing and catalepsy tests. <info type="GeneOrGeneProduct">RESULTS</info>: In the <info type="ChemicalEntity">amphetamine</info>-induced <info type="DiseaseOrPhenotypicFeature">locomotion</info> test, there were significant increases in all movements compared with the <info type="ChemicalEntity">amphetamine</info>-free group. Both <info type="ChemicalEntity">DHEA</info> 50 mg/kg (p<0.05), and 100 mg/kg (p<0.01) significantly decreased all movements compared with the <info type="ChemicalEntity">amphetamine</info>-induced <info type="DiseaseOrPhenotypicFeature">locomotion</info> group. There was a significant difference between groups in the <info type="ChemicalEntity">haloperidol</info>-induced <info type="DiseaseOrPhenotypicFeature">catalepsy</info> test (p<0.05). There was no significant difference between groups in terms of total climbing time in the <info type="ChemicalEntity">apomorphine</info>-induced <info type="DiseaseOrPhenotypicFeature">climbing</info> test (p>0.05). <info type="GeneOrGeneProduct">CONCLUSION</info>: We observed that <info type="ChemicalEntity">DHEA</info> reduced <info type="DiseaseOrPhenotypicFeature">locomotor activity</info> and increased <info type="DiseaseOrPhenotypicFeature">catalepsy</info> at both doses, while it had no effect on <info type="DiseaseOrPhenotypicFeature">climbing behavior</info>. We suggest that <info type="ChemicalEntity">DHEA</info> displays typical <info type="DiseaseOrPhenotypicFeature">neuroleptic-like effects</info>, and may be used in the treatment of <info type="DiseaseOrPhenotypicFeature">schizophrenia</info>.